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A recent study by Leonard, Lebecque, Dingemanse, and
Leal [1] tested the effect of Miglustat, an alpha inhibitor on the
cystic fibrosis conductance regulator gene using total chloride
secretion in the nasal epithelium as the key variable estimated
from basal nasal potential differences. The conclusion was
drawn that “There was no evidence of a treatment effect on any
nasal potential difference variable.” This conclusion may not be
correct because of a slight misinterpretation of their statistical
results. There also is a question of whether longer exposure
periods than 8 days would have produced a more pronounced
effect.
The p and n values in Table 2 of the above study were
converted to standardized effect sizes (r) by the methods
described in Trikalinos et al. [2]. The primary clinical endpoint
of total chloride secretion had an effect size of 19% (r=0 .191).
This is not a large effect size, but it is far from zero. That is,
it would need closer to zero before one could conclude that
no evidence of a treatment effect was found. The fact that this
effect was not statistically significant does not mean that there
was absence of evidence of an effect, which was the conclusion of
the above study. If this pilot study hadmore than 11 participants, it
is possible that this effect would have been statistically significant,
and consequently, some effectiveness cannot be ruled out.
Another possibility that confounds the conclusion concerns
the duration of exposure to Miglustat. The duration of exposure
was 8 days, and this was justified by the finding that plasma
concentrations of Miglustat reached a steady-state within four
days. However, this duration could have been too short to see
long term outcomes from a chronic disease such as cystic
fibrosis. A classic example of the dissociation between plasma
levels and clinical effects is the lack of correlation between the
time to steady the state of plasma levels for amitriptyline and
the antidepressant effects [3].
The above study had many strengths, including the criteria for
selecting the participant, the disclosure of the study limitations,1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.06.003the flow and logic of the article, well-founded hypothesis, and
many more strengths. However, due to the evidence of some
effectiveness of Miglustat on total chloride secretion, the conclu-
sion that no treatment effect was found is probably not justified,
which argues in favor of continued consideration of Miglustat
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